BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
BOSTON--(BUSINESS WIRE)--Boston Cell Standards, a company standardizing tumor tissue testing with the first immunohistochemistry laboratory reference standards, announced the publication of a journal ...
Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...
- Roche's VENTANA ROS1 (SP384) Rabbit Monoclonal Primary Antibody is the first and only in vitro diagnostic ROS1 immunohistochemistry assay on the market - The biomarker may provide a cost-effective ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...
Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx) certification ...
Throughout this timeframe, technological developments spawning next-generation sequencing were leading to dramatic decreases in costs and turnaround times. Alternative business models among new ...
Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results